 |
eculizumab |
|---|---|
| Trade Name | Soliris |
| Orphan Indication | Prevention of delayed graft function after renal transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2014-01-10 00:00:00 |
| Sponsor | Alexion Pharmaceuticals, Inc.;352 Knotter Drive;Cheshire, Connecticut, 06410 |
